0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In [Yahoo! Finance]

Allogene Therapeutics, Inc. (ALLO)  More Company Research Source: Yahoo! Finance
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
regulatory clearance to expand its pivotal Phase 2 ALPHA3 study of cemacabtagene ansegedleucel (cema-cel) into South Korea and Australia. This expansion increases the trial's global footprint to over 80 sites, up from the current 60 in North America, with patient screening and enrollment in these new regions expected to begin in Q2 2026. The study evaluates cema-cel as a first-line consolidation treatment for patients with large B-cell lymphoma/LBCL who show minimal residual disease/MRD after initial chemotherapy. The decision to expand follows positive interim futility analysis data from the first 24 patients, which showed that cema-cel achieved a 58.3% MRD clearance rate compared to just 16.7% in the standard-of-care observation group. Additionally, the therapy was well-tolerated with no reported cases of cytokine release syndrome or neurotoxicity. Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In Allogene Therapeutics Inc. (NASDAQ:ALLO) aims to enroll [Read more]
IMPACT SNAPSHOT EVENT TIME: ALLO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
ALLO alerts
from News Quantified
ALLO
NEWS
ALLO
Earnings
ALLO
Analyst Actions
ALLO
SEC Filings
Stockreport

Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In [Yahoo! Finance]

Allogene Therapeutics, Inc.  (ALLO) 
More Company Research Source: Yahoo! Finance
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
regulatory clearance to expand its pivotal Phase 2 ALPHA3 study of cemacabtagene ansegedleucel (cema-cel) into South Korea and Australia. This expansion increases the trial's global footprint to over 80 sites, up from the current 60 in North America, with patient screening and enrollment in these new regions expected to begin in Q2 2026. The study evaluates cema-cel as a first-line consolidation treatment for patients with large B-cell lymphoma/LBCL who show minimal residual disease/MRD after initial chemotherapy. The decision to expand follows positive interim futility analysis data from the first 24 patients, which showed that cema-cel achieved a 58.3% MRD clearance rate compared to just 16.7% in the standard-of-care observation group. Additionally, the therapy was well-tolerated with no reported cases of cytokine release syndrome or neurotoxicity. Allogene Therapeutics (ALLO): 10 Best Growth Stocks Under $10 to Invest In Allogene Therapeutics Inc. (NASDAQ:ALLO) aims to enroll [Read more]
IMPACT SNAPSHOT
EVENT TIME:
ALLO
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS